{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:24:15Z","timestamp":1793049855602,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4570,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1093\/annonc\/mdl475","type":"journal-article","created":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T01:24:52Z","timestamp":1169083492000},"page":"977-984","source":"Crossref","is-referenced-by-count":524,"title":["Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"G.","family":"Valabrega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdl475_bb0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1093\/annonc\/mdl475_bb0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1093\/annonc\/mdl475_bb0020","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdl475_bb0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1593\/neo.04313","article-title":"Silencing of the HER2\/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2\/neu-overexpressing breast cancer cells","volume":"6","author":"Faltus","year":"2004","journal-title":"Neoplasia"},{"key":"10.1093\/annonc\/mdl475_bb0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3233\/BD-2004-20104","article-title":"Her-2\/neu as a paradigm of a tumor-specific target for therapy","volume":"20","author":"Choudhury","year":"2004","journal-title":"Breast Dis"},{"key":"10.1093\/annonc\/mdl475_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1093\/annonc\/mdl475_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2005.n.011","article-title":"Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer","volume":"6","author":"Montemurro","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14656566.5.1.81","article-title":"Trastuzumab-based combination therapy for breast cancer","volume":"5","author":"Montemurro","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdl475_bb0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl475_bb0055","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0060","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl475_bb0065","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdl475_bb0070","first-page":"S5","volume":"94","author":"Slamon","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdl475_bb0075","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0080","first-page":"1340","article-title":"HER2 testing and correlation with efficacy of trastuzumab therapy","volume":"16","author":"Fornier","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdl475_bb0085","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry","volume":"18","author":"Pauletti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0090","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1016146130767","article-title":"Evaluation of HER-2\/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2\/NEU testing","volume":"74","author":"Gancberg","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdl475_bb0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3816\/CBC.2005.n.026","article-title":"Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab","volume":"6","author":"Mass","year":"2005","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0100","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.1999.17.7.1983","article-title":"Specificity of HercepTest in determining HER-2\/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system","volume":"17","author":"Jacobs","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0105","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0301-472X(99)00089-2","article-title":"Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2\/neu","volume":"27","author":"Cooley","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1093\/annonc\/mdl475_bb0110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01518520","article-title":"Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies","volume":"37","author":"Lewis","year":"1993","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdl475_bb0115","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdl475_bb0120","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0125","first-page":"2440","article-title":"Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study","volume":"9","author":"Repka","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0130","first-page":"5123","article-title":"NH2-terminally truncated HER-2\/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer","volume":"58","author":"Christianson","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0135","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/annonc\/mdi059","article-title":"Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate","volume":"16","author":"Fornier","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0145","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-0385-3","article-title":"Monitoring of serum Her-2\/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer","volume":"10","author":"Kostler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0150","first-page":"72","article-title":"Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth","volume":"1","author":"Sarup","year":"1991","journal-title":"Growth Regul"},{"key":"10.1093\/annonc\/mdl475_bb0155","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1038\/sj.onc.1208478","article-title":"TGFalpha expression impairs trastuzumab-induced HER2 downregulation","volume":"24","author":"Valabrega","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdl475_bb0160","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol Biol Cell"},{"key":"10.1093\/annonc\/mdl475_bb0165","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1093\/annonc\/mdi405","article-title":"Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma","volume":"16","author":"Delord","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdl475_bb0175","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1038\/sj.onc.1203685","article-title":"Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis","volume":"19","author":"Yen","year":"2000","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdl475_bb0180","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Tumour biology: herceptin acts as an anti-angiogenic cocktail","volume":"416","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdl475_bb0185","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/cncr.11656","article-title":"Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone","volume":"98","author":"Klos","year":"2003","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdl475_bb0190","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/annonc\/12.suppl_1.S21","article-title":"Modulation of p27\/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling","volume":"12","author":"Lane","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0195","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","article-title":"Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)","volume":"93","author":"Lu","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdl475_bb0200","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0205","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.yexcr.2004.12.008","article-title":"Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2\/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation","volume":"304","author":"Diermeier","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1093\/annonc\/mdl475_bb0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0215","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bjc.6602507","article-title":"A modified trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer","volume":"92","author":"Bussolati","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0220","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2005.12.157","article-title":"Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies","volume":"23","author":"Spector","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0225","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1038\/sj.onc.1208774","article-title":"Combining lapatinib (GW57 2016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells","volume":"24","author":"Xia","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdl475_bb0230","first-page":"203s","article-title":"A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer","volume":"23","author":"Gomez","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0235","first-page":"193s","article-title":"Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer","volume":"23","author":"Blackwell","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0240","article-title":"EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed\/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response","volume":"24","author":"Spector","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0245","unstructured":"GeyerCameronLindquistA phase III randomized, open label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory or advanced metastatic breast cancer (EGF 100151). ASCO Scientific Special Session: Lapatinib in Trastuzumab Resistant Breast Cancerhttp:\/\/www.asco.org (31 August 2006, date last accessed)."},{"key":"10.1093\/annonc\/mdl475_bb0250","article-title":"Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer","volume":"24","author":"Lin","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0255","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/jco.2005.23.16_suppl.559","article-title":"A phase I, open-label study of lapatinib (GW57 2016) plus trastuzumab; a clinically active regimen","volume":"23","author":"Storniolo","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0260","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/annonc\/mdf020","article-title":"Cooperative inhibitory effect of ZD 1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth","volume":"13","author":"Normanno","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0265","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-03-0244","article-title":"Treatment of HER-2\/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD 1839): drug combination effects on tumor growth, HER-2\/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction","volume":"10","author":"Warburton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0270","first-page":"S15","article-title":"ECOG1100: a phase I\u2013II study of combined blockade of the erbB receptor network with trastuzmab and gefitinib ([Isquo]Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca)","volume":"88","author":"Arteaga","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdl475_bb0275","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/annonc\/mdi325","article-title":"Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?","volume":"16","author":"Normanno","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","article-title":"Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth","volume":"2","author":"Agus","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdl475_bb0285","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdl475_bb0290","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdl475_bb0295","first-page":"44a","article-title":"First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy","volume":"21","author":"Chan","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0300","first-page":"S124","article-title":"Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF)","volume":"88","author":"Pegram","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdl475_bb0305","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1073\/pnas.89.13.5867","article-title":"Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin","volume":"89","author":"Batra","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdl475_bb0310","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/1097-0215(20001015)88:2<267::AID-IJC19>3.0.CO;2-G","article-title":"A novel recombinant fusion toxin targeting HER-2\/NEU-over-expressing cells and containing human tumor necrosis factor","volume":"88","author":"Rosenblum","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdl475_bb0320","first-page":"46s","article-title":"registHER: a prospective, longitudinal cohort study of women with HER2 positive metastatic breast cancer","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0325","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3816\/CBC.2004.n.010","article-title":"Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories","volume":"5","author":"Gelmon","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0330","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3816\/CBC.2003.n.017","article-title":"Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group","volume":"4","author":"Fountzilas","year":"2003","journal-title":"Clin Breast Cancer"},{"key":"10.1093\/annonc\/mdl475_bb0335","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2004.06.557","article-title":"Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression","volume":"22","author":"Tripathy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdl475_bb0340","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1634\/theoncologist.11-4-318","article-title":"Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy","volume":"11","author":"Montemurro","year":"2006","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdl475_bb0345","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1200\/JCO.2005.05.177","article-title":"Continuation of trastuzumab beyond disease progression","volume":"23","author":"Montemurro","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/6\/977\/664538\/mdl475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T12:38:45Z","timestamp":1683722325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0923753419379013"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdl475","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}